Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Pharming Group ( (PHGUF) ).
Pharming Technologies B.V., a subsidiary of Pharming Group N.V., has successfully completed a cash offer acquisition for 87.7% of shares in Abliva AB. The company intends to acquire more than 90% of shares to initiate a compulsory acquisition procedure and delist Abliva from Nasdaq Stockholm, extending the acceptance period for remaining shareholders.
More about Pharming Group
Pharming Group is a biotechnology company focused on developing and commercializing innovative protein replacement therapies and precision medicines for the treatment of rare diseases. The company operates globally, with a significant presence in the European market.
YTD Price Performance: -11.63%
Average Trading Volume: 1,783
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $590.3M
For an in-depth examination of PHGUF stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue